Send to

Choose Destination
See comment in PubMed Commons below
Invest New Drugs. 2009 Aug;27(4):389-90. doi: 10.1007/s10637-008-9196-2. Epub 2008 Nov 8.

Blackberry-induced hand-foot skin reaction to sunitinib.

Author information

Department of Dermatology, Northwestern University's Feinberg School of Medicine, Chicago, IL 60611, USA.

Erratum in

  • Invest New Drugs. 2009 Aug;27(4):391.


Sunitinib is an orally administered small molecule that was approved by the US Food and Drug Administration in January 2006 as monotherapy for the treatment of patients with advanced renal cell carcinoma (RCC) and patients with gastrointestinal stromal tumor after disease progression on or intolerance to imatinib mesylate. Data pooled from multiple sunitinib dose-escalation trials showed that sunitinib is associated with various adverse events, with HFSR occurring in up to 20% of patients. We describe a 48-year-old woman with a history of metastatic colorectal cancer treated with single-agent sunitinib who developed pain and tenderness in areas of friction secondary to Blackberry use, and was diagnosed with trauma-induced hand-foot skin reaction (HFSR) secondary to sunitinib therapy.

[Indexed for MEDLINE]
PubMed Commons home

PubMed Commons

How to join PubMed Commons

    Supplemental Content

    Full text links

    Icon for Springer
    Loading ...
    Support Center